Lynley D Pound1, Paul Kievit, Kevin L Grove. 1. aDivision of Diabetes, Obesity, & Metabolism bDivision of Reproductive & Developmental Sciences, Oregon National Primate Research Center, Beaverton, Oregon, USA.
Abstract
PURPOSE OF THE REVIEW: Although rodent models provide insight into the mechanisms underlying type 2 diabetes mellitus (T2DM), they are limited in their translatability to humans. The nonhuman primate (NHP) shares important metabolic similarities with the human, making it an ideal model for the investigation of type 2 diabetes and use in preclinical trials. This review highlights the key contributions in the field over the last year using the NHP model. RECENT FINDINGS: The NHP has not only provided novel insight into the normal and pathological processes that occur within the islet, but has also allowed for the preclinical testing of novel pharmaceutical targets for obesity and T2DM. Particularly, administration of fibroblast growth factor-21 in the NHP resulted in weight loss and improvements in metabolic health, supporting rodent studies and recent clinical trials. In addition, the NHP was used to demonstrate that a novel melanocortin-4 receptor agonist did not cause adverse cardiovascular effects. Finally, this model has been used to provide evidence that glucagon-like peptide-1-based therapies do not induce pancreatitis in the healthy NHP. SUMMARY: The insight gained from studies using the NHP model has allowed for a better understanding of the processes driving T2DM and has promoted the development of well tolerated and effective treatments.
PURPOSE OF THE REVIEW: Although rodent models provide insight into the mechanisms underlying type 2 diabetes mellitus (T2DM), they are limited in their translatability to humans. The nonhuman primate (NHP) shares important metabolic similarities with the human, making it an ideal model for the investigation of type 2 diabetes and use in preclinical trials. This review highlights the key contributions in the field over the last year using the NHP model. RECENT FINDINGS: The NHP has not only provided novel insight into the normal and pathological processes that occur within the islet, but has also allowed for the preclinical testing of novel pharmaceutical targets for obesity and T2DM. Particularly, administration of fibroblast growth factor-21 in the NHP resulted in weight loss and improvements in metabolic health, supporting rodent studies and recent clinical trials. In addition, the NHP was used to demonstrate that a novel melanocortin-4 receptor agonist did not cause adverse cardiovascular effects. Finally, this model has been used to provide evidence that glucagon-like peptide-1-based therapies do not induce pancreatitis in the healthy NHP. SUMMARY: The insight gained from studies using the NHP model has allowed for a better understanding of the processes driving T2DM and has promoted the development of well tolerated and effective treatments.
Authors: Paul B Higgins; Robert E Shade; Irám P Rodríguez-Sánchez; Magdalena Garcia-Forey; M Elizabeth Tejero; V Saroja Voruganti; Shelley A Cole; Anthony G Comuzzie; Franco Folli Journal: Am J Physiol Endocrinol Metab Date: 2016-08-16 Impact factor: 4.310
Authors: Jonathan Q Purnell; Henryk F Urbanski; Paul Kievit; Charles T Roberts; Cynthia L Bethea Journal: Endocrinology Date: 2019-04-01 Impact factor: 4.736
Authors: Maximilian Kleinert; Christoffer Clemmensen; Susanna M Hofmann; Mary C Moore; Simone Renner; Stephen C Woods; Peter Huypens; Johannes Beckers; Martin Hrabe de Angelis; Annette Schürmann; Mostafa Bakhti; Martin Klingenspor; Mark Heiman; Alan D Cherrington; Michael Ristow; Heiko Lickert; Eckhard Wolf; Peter J Havel; Timo D Müller; Matthias H Tschöp Journal: Nat Rev Endocrinol Date: 2018-01-19 Impact factor: 43.330
Authors: Vladimir Vigdorovich; Brian G Oliver; Sara Carbonetti; Nicholas Dambrauskas; Miles D Lange; Christina Yacoob; Will Leahy; Jonathan Callahan; Leonidas Stamatatos; D Noah Sather Journal: Clin Transl Immunology Date: 2016-07-22